Your browser doesn't support javascript.
loading
[Clinical features and treatment outcome of extranodal nasal-type NK/T-cell lymphoma of the extra-upper aerodigestive tract].
Zhao, Y T; Wang, Y; Qi, S N; Yang, Y; He, X; Zhang, Y J; Huang, H Q; Zhang, L L; Wu, G; Qu, B L; Qian, L T; Hou, X R; Zhang, F Q; Qiao, X Y; Wang, H; Li, G F; Zhu, Y; Cao, J Z; Wu, J X; Wu, T; Zhu, S Y; Shi, M; Xu, L M; Yuan, Z Y; Su, H; Song, Y Q; Zhu, J; Li, Y X.
Afiliação
  • Zhao YT; Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
  • Wang Y; Department of Radiation Oncology, Chongqing University Cancer Hospital & Chongqing Cancer Hospital, Chongqing 400030, China.
  • Qi SN; Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
  • Yang Y; Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
  • He X; Department of Radiation Oncology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing 210009, China.
  • Zhang YJ; Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center; Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.
  • Huang HQ; Department of Medical Oncology, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center; Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.
  • Zhang LL; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
  • Wu G; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
  • Qu BL; Department of Radiation Oncology, The General Hospital of Chinese People's Liberation Army, Beijing 100853, China.
  • Qian LT; Department of Radiation Oncology, The Affiliated Provincial Hospital of Anhui Medical University, Hefei 230001, China.
  • Hou XR; Department of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing 100730, China.
  • Zhang FQ; Department of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing 100730, China.
  • Qiao XY; Department of Radiation Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China.
  • Wang H; Department of Radiation Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang 330029, China.
  • Li GF; Department of Radiation Oncology, Beijing Hospital, National Geriatric Medical Center, Beijing 100730, China.
  • Zhu Y; Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou 310022, China.
  • Cao JZ; Department of Radiation Oncology, Shanxi Cancer Hospital and the Affiliated Cancer Hospital of Shanxi Medical University, Taiyuan 030013, China.
  • Wu JX; Department of Radiation Oncology, Fujian Provincial Cancer Hospital, Fuzhou 350014, China.
  • Wu T; Department of Radiation Lymphoma, Affiliated Hospital of Guizhou Medical University, Guizhou Cancer Hospital, Guiyang 550001, China.
  • Zhu SY; Department of Radiation Oncology, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Changsha 410013, China.
  • Shi M; Department of Radiation Oncology, Xijing Hospital of Fourth Military Medical University, Xi'an 710032, China.
  • Xu LM; Department of Radiation Oncology, Tianjin Medical University Cancer Institute & Hospital, Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin 300060, China.
  • Yuan ZY; Department of Radiation Oncology, Tianjin Medical University Cancer Institute & Hospital, Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin 300060, China.
  • Su H; Department of Oncology, The Fifth Medical Center of PLA General Hospital, Beijing 100071, China.
  • Song YQ; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, China.
  • Zhu J; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, China.
  • Li YX; Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Zhonghua Zhong Liu Za Zhi ; 43(7): 787-794, 2021 Jul 23.
Article em Zh | MEDLINE | ID: mdl-34289574
ABSTRACT

Objective:

To investigate the clinical features and prognosis of extranodal nasal-type NK/T-cell lymphoma of the extra-upper aerodigestive tract (extra-UADT NKTCL).

Methods:

The clinical data of 159 patients with extra-UADT NKTCL from the China Lymphoma Collaborative Group (CLCG) database between November 2001 and December 2015 were retrospectively analyzed. Kaplan-Meier survival analysis and Log-rank test were used to evaluate the prognosis. The Cox regression model is used for multi-factor analysis.

Results:

Extra-UADT NKTCL commonly occurs in skin and soft tissues (106/159, 66.7%) and gastrointestinal tract (31/159, 19.5%). The incidences of elevated lactate dehydrogenase (LDH) and Ann Arbor Ⅲ~Ⅳ stage were 47.8% (76/159) and 64.2% (102/159), respectively. The 3-year overall survival (OS) and progression-free survival (PFS) rates were 43.6% and 27.9%, respectively. The corresponding OS rates of primary skin/soft tissue site and gastrointestinal tract site were 41.0% and 59.4% (P=0.281), while the PFS rates were 24.8% and 48.3%, respectively (P=0.109). Combined modality treatment improved the 3-year OS of all the patients (58.4% vs 33.9%, P=0.001) and 3-year PFS (40.7% vs 20.7%, P=0.008) when compared with chemotherapy alone. LDH elevation, Ann Arbor synthesising and ≥2 junction external bits were intrusive as independent risk factors for total survival (P<0.05), LDH elevation and ≥2 junction outer bits were intrusive as independent risk factors for progressionless survival(P<0.05). The distant extranodal dissemination was the primary failure patterns.

Conclusions:

Extra-UADT NKTCL appears to have distinct clinical characteristics and poor outcome. Compared with chemotherapy alone, combined modality treatment may improve the prognosis of patients with extra-UADT NKTCL.
Assuntos
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Linfoma Extranodal de Células T-NK Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans País/Região como assunto: Asia Idioma: Zh Revista: Zhonghua Zhong Liu Za Zhi Ano de publicação: 2021 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Linfoma Extranodal de Células T-NK Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans País/Região como assunto: Asia Idioma: Zh Revista: Zhonghua Zhong Liu Za Zhi Ano de publicação: 2021 Tipo de documento: Article País de afiliação: China